A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Incyte Corporation

Summary

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * ≥18 years old * Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol. * Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study. * ECOG performance status score of 0 or 1. * Willingness to undergo pre- and o…

Interventions

Drug
INCA33890
INCA33890 will be administered at protocol defined dose.
Drug
bevacizumab
Bevacizumab will be administered at protocol defined dose.
Drug
FOLFIRI
FOLFIRI will be administered at protocol defined dose.
Drug
FOLFOX
FOLFOX will be administered at protocol defined dose.
Drug
Cetuximab
Cetuximab will be administered at protocol defined dose.
Drug
ADG126
ADG126 will be administered at protocol defined dose.

Locations (39)

The Angeles Clinic and Research Institute
Los Angeles, California
Valkyrie Clinical Trials
Los Angeles, California
Dana Farber Cancer Institute
Boston, Massachusetts
Cancer and Hematology Centers of Western Michigan-Start Midwest
Grand Rapids, Michigan
Hackensack University Medical Center
Hackensack, New Jersey
Nyu Langone Health - Long Island Hospital
Mineola, New York